The Relative Strength (RS) Rating for Amdocs moved up into a higher percentile Monday, as it got a lift from 69 to 73.
IBD's unique rating tracks share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating of above 80 as they launch their biggest price moves. See if Amdocs can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Amdocs is building a consolidation with a 93.34 buy point. See if it can clear the breakout price in volume at least 40% higher than normal.
Amdocs posted 6% earnings growth last quarter, while sales growth came in at -11%. Look for the next report on or around May 7.
The company holds the No. 13 rank among its peers in the Computer-Technical Services industry group. IBEX, Innodata and UL Solutions are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
